Protein Induced by Vitamin K Antagonist-II (PIVKA-II) Sebagai Tumor Marker Pada Karsinoma Sel Hati
##plugins.themes.academic_pro.article.main##
Published
Apr 23, 2025
Abstract
Liver cell carcinoma (KSH) is a primary malignant liver tumor originating from hepatocyte cells that grow abnormally and is the most common primary liver cancer. Even though there are quite a lot of surveillance methods and diagnostic guidelines for KSH, only 40% of KSH cases are diagnosed at an early stage. Detecting KSH at an early stage is an effective way to increase the long-term survival rate of KSH patients. One way to detect KSH early is by examining tumor markers in at-risk populations. Protein induced by vitamin K antagonist-II (PIVKA-II) is a tumor marker that can be used to replace the role of Alpha-fetoprotein (AFP) not only for surveillance, but also in the diagnosis and prognosis of KSH and from several studies, PIVKA-II is superior with higher sensitivity and specificity than AFP which is a conventional KSH tumor marker.
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Hak Cipta :
Penulis yang mempublikasikan manuskripnya di jurnal ini menyetujui ketentuan berikut:
- Hak cipta pada setiap artikel adalah milik penulis.
- Penulis mengakui bahwa Ranah Research : Journal of Multidisciplinary Research and Development berhak menjadi yang pertama menerbitkan dengan lisensi Creative Commons Attribution 4.0 International (Attribution 4.0 International CC BY 4.0) .
- Penulis dapat mengirimkan artikel secara terpisah, mengatur distribusi non-eksklusif manuskrip yang telah diterbitkan dalam jurnal ini ke versi lain (misalnya, dikirim ke repositori institusi penulis, publikasi ke dalam buku, dll.), dengan mengakui bahwa manuskrip telah diterbitkan pertama kali di Ranah Research.
How to Cite
Yudanda, V. and Arnelis, A. (2025) “Protein Induced by Vitamin K Antagonist-II (PIVKA-II) Sebagai Tumor Marker Pada Karsinoma Sel Hati”, Ranah Research : Journal of Multidisciplinary Research and Development, 7(4), pp. 2365-2372. doi: 10.38035/rrj.v7i4.1466.
References
Menteri Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Karsinoma Sel Hati Pada Dewasa. 2022.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN 2022; 71:209–49
Foglia, Beatrice et al. “Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment.” International journal of molecular sciences. 2023: 24 (15): 122-24.
Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. Journal of Liver Cancer 2024; 24 (1): 62-70.
Budihusodo U. Karsinoma hati dalam Buku Ajar Ilmu Penyakit Dalam Jilid 3 Edisi Keenam. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia. 2014; 3040–6
Patel, Nishant et al. “Diagnostic delays are common among patients with hepatocellular carcinoma.” Journal of the National Comprehensive Cancer Network: JNCCN. 2015: 13 (5): 543-9.
Choi, Debra T et al. “Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis.” Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association.2021: 19 (8) : 1679-87.
Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007; 45:1169–1179.
Liu, Siyu et al. “Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis.” Journal of clinical medicine. 2022: 11(7) ; 5075.
Yang, Ju Dong et al. “Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States.” Cancer. 2017: 123 (1) : 81- 89
Jasirwan COM, Hasan I, Sulaiman AS, Lesmana CR, Kurniawan J, Kalista KF et al. Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia. Current Problems in Cancer. 2019; 14(15): 1– 11
Imalatul M. Analisis survival pasien karsinoma sel hati di RSUP Dr.M. Djamil Kota Padang Tahun 2018-2023. Universitas Andalas. 2014.
Suresh D, Srinivas AN and Kumar DP (2020) Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front. Oncol.10:601710.
Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and Worldwide. J Liver Cancer 2024;24(1):62-70.
Nurdjanah S. Sirosis hati dalam Buku Ajar Ilmu Penyakit Dalam Jilid I. Edisi Keenam. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia. 2014
Osna, Natalia A et al. “Alcoholic Liver Disease: Pathogenesis and Current Management.” Alcohol research: current reviews vol. 38,2 (2017): 147-161.
Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weight connection. Hepatology. 2010; 51(5): 1820– 32
Kaur K, Allahbadia G, Singh M. The Association of Non-Viral Liver Diseases from NAFLD to NASH to HCC with the Pandemic of Obesity, Type 2 Diabetes, or Diabesity & Metabolic Syndrome Etiopathogenetic Correlation along with Utilization for Diagnostic & Therapeutic Purposes-A Systematic Review. Journal of Endocrinology Research, 3(2), 10–33.
Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: risk factors, diagnosis and treatment. Macedonian Journal of Medical Sciences. 2015; 3 (4): 7326
Farazi, P., DePinho, R. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006: 5 (6): 674–87.
Rasyid A. Pentingnya peranan radiologi dalam deteksi dini dan pengobatan kanker hati primer. USU press. 2006.
Budihusodo U. Karsinoma Sel Hati. Dalam: Siti Setiadi, Idrus Alwi dan Ari Fahrial Syam. Buku Ajar Ilmu Penyakit Dalam. Ed IV-Jilid III. Interna Publishing. 2014: 3040-46.
Hanif, Hira et al. “Update on the applications and limitations of alpha- fetoprotein for hepatocellular carcinoma.” World journal of gastroenterology vol. 28,2 (2022): 216-29.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia- Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11: 317-70
Agopian VG, Harlander-Locke MP, Markovic D, Zarrinpar A, Kaldas FM, Cheng EY, Yersiz H, Farmer DG, Hiatt JR, Busuttil RW. Evaluation of Patients with Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein. JAMA Surg 2017; 152: 55-64
Carr BI, Akkiz H, Üsküdar O, Yalçın K, Guerra V et al. HCC with low- and normal-serum alpha-fetoprotein levels. Clin Pract (Lond). 2018; 15: 453-64
Manuc D, Preda CM, Sandra I, Baicus C, Cerban R et al. Signification of Serum Alpha-Fetoprotein Levels in Cases of Compensated Cirrhosis and Hepatitis C Virus without Hepatocellular Carcinoma. J Med Life 2020; 13: 68-74
Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res. 2014; 44(10): E11-25
Zhang YS, Chu JH, Cui SX, Song ZY, Qu XJ. Des-γ-carboxyprothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma. Cellular Physiology and Biochemistry, 2014; 34(3): 903-15.
Inagaki Y, Tang W, Makuuchi M, Hasegawa, Sugawara Y et al. Clinical and Molecular Insight into the hepatocellular carcinoma tumor marker des-y- carboxyprothrombin. Liver International. 2010: 31 (1); 22-35.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN 2022; 71:209–49
Foglia, Beatrice et al. “Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment.” International journal of molecular sciences. 2023: 24 (15): 122-24.
Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. Journal of Liver Cancer 2024; 24 (1): 62-70.
Budihusodo U. Karsinoma hati dalam Buku Ajar Ilmu Penyakit Dalam Jilid 3 Edisi Keenam. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia. 2014; 3040–6
Patel, Nishant et al. “Diagnostic delays are common among patients with hepatocellular carcinoma.” Journal of the National Comprehensive Cancer Network: JNCCN. 2015: 13 (5): 543-9.
Choi, Debra T et al. “Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis.” Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association.2021: 19 (8) : 1679-87.
Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007; 45:1169–1179.
Liu, Siyu et al. “Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis.” Journal of clinical medicine. 2022: 11(7) ; 5075.
Yang, Ju Dong et al. “Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States.” Cancer. 2017: 123 (1) : 81- 89
Jasirwan COM, Hasan I, Sulaiman AS, Lesmana CR, Kurniawan J, Kalista KF et al. Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia. Current Problems in Cancer. 2019; 14(15): 1– 11
Imalatul M. Analisis survival pasien karsinoma sel hati di RSUP Dr.M. Djamil Kota Padang Tahun 2018-2023. Universitas Andalas. 2014.
Suresh D, Srinivas AN and Kumar DP (2020) Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front. Oncol.10:601710.
Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and Worldwide. J Liver Cancer 2024;24(1):62-70.
Nurdjanah S. Sirosis hati dalam Buku Ajar Ilmu Penyakit Dalam Jilid I. Edisi Keenam. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia. 2014
Osna, Natalia A et al. “Alcoholic Liver Disease: Pathogenesis and Current Management.” Alcohol research: current reviews vol. 38,2 (2017): 147-161.
Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weight connection. Hepatology. 2010; 51(5): 1820– 32
Kaur K, Allahbadia G, Singh M. The Association of Non-Viral Liver Diseases from NAFLD to NASH to HCC with the Pandemic of Obesity, Type 2 Diabetes, or Diabesity & Metabolic Syndrome Etiopathogenetic Correlation along with Utilization for Diagnostic & Therapeutic Purposes-A Systematic Review. Journal of Endocrinology Research, 3(2), 10–33.
Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: risk factors, diagnosis and treatment. Macedonian Journal of Medical Sciences. 2015; 3 (4): 7326
Farazi, P., DePinho, R. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006: 5 (6): 674–87.
Rasyid A. Pentingnya peranan radiologi dalam deteksi dini dan pengobatan kanker hati primer. USU press. 2006.
Budihusodo U. Karsinoma Sel Hati. Dalam: Siti Setiadi, Idrus Alwi dan Ari Fahrial Syam. Buku Ajar Ilmu Penyakit Dalam. Ed IV-Jilid III. Interna Publishing. 2014: 3040-46.
Hanif, Hira et al. “Update on the applications and limitations of alpha- fetoprotein for hepatocellular carcinoma.” World journal of gastroenterology vol. 28,2 (2022): 216-29.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia- Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11: 317-70
Agopian VG, Harlander-Locke MP, Markovic D, Zarrinpar A, Kaldas FM, Cheng EY, Yersiz H, Farmer DG, Hiatt JR, Busuttil RW. Evaluation of Patients with Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein. JAMA Surg 2017; 152: 55-64
Carr BI, Akkiz H, Üsküdar O, Yalçın K, Guerra V et al. HCC with low- and normal-serum alpha-fetoprotein levels. Clin Pract (Lond). 2018; 15: 453-64
Manuc D, Preda CM, Sandra I, Baicus C, Cerban R et al. Signification of Serum Alpha-Fetoprotein Levels in Cases of Compensated Cirrhosis and Hepatitis C Virus without Hepatocellular Carcinoma. J Med Life 2020; 13: 68-74
Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res. 2014; 44(10): E11-25
Zhang YS, Chu JH, Cui SX, Song ZY, Qu XJ. Des-γ-carboxyprothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma. Cellular Physiology and Biochemistry, 2014; 34(3): 903-15.
Inagaki Y, Tang W, Makuuchi M, Hasegawa, Sugawara Y et al. Clinical and Molecular Insight into the hepatocellular carcinoma tumor marker des-y- carboxyprothrombin. Liver International. 2010: 31 (1); 22-35.